Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 1
1998 2
2000 3
2001 4
2002 3
2003 2
2004 1
2005 5
2006 1
2007 5
2008 2
2009 4
2010 6
2011 4
2012 8
2013 4
2014 2
2015 4
2016 3
2017 3
2019 1
2021 1
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 31530791

63 results

Results by year

Filters applied: . Clear all
Page 1
Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes.
Jones A, O'Brien M, Sommer H, Nowara E, Welt A, Pienkowski T, Rolski J, Pham ML, Perraud K, Trillet-Lenoir V. Jones A, et al. Cancer Chemother Pharmacol. 2010 Mar;65(4):755-63. doi: 10.1007/s00280-009-1081-y. Epub 2009 Aug 9. Cancer Chemother Pharmacol. 2010. PMID: 19669644 Clinical Trial.
Salvage chemotherapy with high-dose leucovorin (LV) and 48-hour continuous infusion (CI) of 5-fluorouracil (5-FU) in combination with conventional doses of cyclophosphamide (CPM) in patients with metastatic breast cancer (MBC) pretreated with anthracycline and taxanes.
Kalbakis K, Kouroussis C, Kakolyris S, Mavroudis D, Souglakos J, Agelaki S, Vamvakas L, Christodoulakis M, Stylianou K, Georgoulias V. Kalbakis K, et al. Br J Cancer. 2001 Sep 14;85(6):798-802. doi: 10.1054/bjoc.2001.2001. Br J Cancer. 2001. PMID: 11556827 Free PMC article. Clinical Trial.
Efficacy and safety of eribulin as first- to third-line treatment in patients with advanced or metastatic breast cancer previously treated with anthracyclines and taxanes.
Maeda S, Saimura M, Minami S, Kurashita K, Nishimura R, Kai Y, Yano H, Mashino K, Mitsuyama S, Shimokawa M, Tamura K; Kyushu Breast Cancer Study Group. Maeda S, et al. Breast. 2017 Apr;32:66-72. doi: 10.1016/j.breast.2016.12.017. Epub 2017 Jan 3. Breast. 2017. PMID: 28056400 Clinical Trial.
63 results